Biotechnology News 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 28.
Human-Eye Precursor Grown from Stem Cell
From Nature magazine [More]
Source: Scientific American Topic - Stem Cell Research - June 15, 2012 Category: Stem Cells Tags: Health,Medical Technology,Biotechnology,Biotechnology,Biology,More Science Source Type: news
Whole Genome DNA Sequencing's Impact on Health Care
Advances in high throughput DNA sequencing are bringing costs down to the point where this technology can transition from basic research to a routine medical use. However, there is a lot of discussion how this new extensive genetic information will really affect health care....Read Full Post
Source: About.com Biotech Biomedical - June 15, 2012 Category: Biotechnology Source Type: news
Roche Closing NimbleGen and Pulling Out of DNA Microarray Market
Following the collapse of Roche's attempted acquisition of Illumina, Roche continues to try and sort out its genomics strategy.
A couple weeks ago, Roche announced it would be closing down its Nimblegen DNA microarray business. Roche will cease all Nimblegen operations in Iceland and Europe, and cut out half the US operation in Madison, eliminating about 120 employees....Read Full Post
Source: About.com Biotech Biomedical - June 15, 2012 Category: Biotechnology Source Type: news
Acorda initiates proof-of-concept study of Ampyra
Acorda Therapeutics, a biotechnology company, has enrolled the first patient in an Ampyra (dalfampridine) proof-of-concept study in patients with post-stroke deficits.
Source: Drug Development Technology - June 14, 2012 Category: Pharmaceuticals Source Type: news
Tata Group weighs options to exit Advinus Therapeutics
Tata Group-owned drug discovery and services firm Advinus Therapeutics has initiated talks with a few foreign drug companies that could lead it to exit the company.
Source: The Economic Times Healthcare and Biotech News - June 14, 2012 Category: Pharmaceuticals Source Type: news
Timber Creek student wins scholarship with paid medical internships
It wasn't so long ago that the lab rat was supposed to displace Mickey as the state's most important rodent.
Turns out Mickey doesn't have anything to worry about.
The biotechnology industry and its rats are nowhere close to nudging tourism out of the...
Source: OrlandoSentinel: Medical Research - June 14, 2012 Category: American Health Source Type: news
Dendreon Shareholders Complain About Stock Losses
[the Seattle
Times]
From Seattle Times (WA) (June 13, 2012)
June 13--Dendreon shareholders strafed the Seattle biotechnology
company’s leadership with criticism at Wednesday’s
annual...
Source: Drugs.com - Pharma News - June 14, 2012 Category: Pharmaceuticals Source Type: news
Small Comfort: Nanomedicine Able to Penetrate Bodily Defenses
Tears and a runny nose can be unpleasant on a windy day, but these mucosal secretions play a vital role in protecting the body from viruses and other malicious microbes. Unfortunately, mucus is also adept at washing away medication designed to treat infections and inflammation that occur when an infectious agent is successful in penetrating the body's defenses [More]
Source: Scientific American Topic - Biotechnology - June 14, 2012 Category: Biotechnology Tags: Technology,Chemistry,Health,Pharmaceuticals,Biotechnology,Biotechnology,Infectious Diseases,Medical Technology,Biology,More Science Source Type: news
Body Count: Taking Stock of All the Bugs That Call Humans Home
The microbes that inhabit our bodies are intimately involved in human health and disease yet we still know relatively little about them. A new major census of these tiny symbionts has revealed that they are an even more diverse bunch than was once presumed. [More]
Source: Scientific American Topic - Biotechnology - June 13, 2012 Category: Biotechnology Tags: Health,Health,Technology,Society & Policy,Everyday Science,Pharmaceuticals,Evolution,Evolutionary Biology,Biotechnology,Biotechnology,Infectious Diseases,Medical Technology,Biology,More Science Source Type: news
Upsher-Smith bids for UK biotech group
The move marks confidence in the UK’s continued ability to create life science businesses, while highlighting the small number able to survive
Source: FT.com - Drugs and Healthcare - June 13, 2012 Category: Pharmaceuticals Source Type: news
Multiplicom Gets $250K to Make Prenatal Genetic Test Using Maternal Blood
Last week, Belgium start-up Multiplicom received a $260,000 grant from the Flemish Agency for Innovation by Science and Technology to develop a genetic test that uses blood samples from the pregnant woman to detect fetal abnormalities, specifically chromosome copy number variations that cause disorders like Down's syndrome....Read Full Post
Source: About.com Biotech Biomedical - June 12, 2012 Category: Biotechnology Source Type: news
Comparing Boston and San Francisco Biotech Clusters
The regions around Boston and San Francisco have hosted the largest biotech business clusters since the industry sector started in the 1970s. Almost half of US biotech investment goes to these areas and a quarter of US biotech companies are located in these two clusters. How do these regions compare in terms of the types of biotech companies, size of biotech communities, and amount of biotech investment?...Read Full Post
Source: About.com Biotech Biomedical - June 12, 2012 Category: Biotechnology Source Type: news
VaxInnate initiates Phase 1 trial of H5 vaccine candidate
VaxInnate, a privately-held biotechnology company, has begun patient enrolment in a Phase 1 clinical trial evaluating its H5 vaccine candidate, VAX161, for the prevention of pandemic avian influenza or bird flu.
Source: Drug Development Technology - June 12, 2012 Category: Pharmaceuticals Source Type: news
30 under 30: Exploring Nature with the Tools of Physics
The annual Lindau Nobel Laureate Meeting brings a wealth of scientific minds to the shores of Germany’s Lake Constance. Every summer at Lindau, dozens of Nobel Prize winners exchange ideas with hundreds of young researchers from around the world. Whereas the Nobelists are the marquee names, the younger contingent is an accomplished group in its own right. In advance of this year’s meeting, which focuses on physics, we are profiling several promising attendees under the age of 30. The profile below is the fourth in a series of 30. [More]
Source: Scientific American Topic - Biotechnology - June 12, 2012 Category: Biotechnology Tags: More Science,Chemistry,Health,Biotechnology,More Science,Biotechnology,Biology,Physics Source Type: news
U.S. Marshals seize dietary supplements in Maine
U.S. Marshals recently seized misbranded Global Biotechnologies dietary supplements at the request of
the FDA, and per a warrant issued by the U.S. District Court for the District of Maine, according to an FDA
statement.
Source: Drug Topics - Top News - June 12, 2012 Category: Drugs & Pharmacology Source Type: news
30 under 30: Pushing Physics forward in Service of Biology
The annual Lindau Nobel Laureate Meeting brings a wealth of scientific minds to the shores of Germany’s Lake Constance. Every summer at Lindau, dozens of Nobel Prize winners exchange ideas with hundreds of young researchers from around the world. Whereas the Nobelists are the marquee names, the younger contingent is an accomplished group in its own right. In advance of this year’s meeting, which focuses on physics, we are profiling several promising attendees under the age of 30. The profile below is the second in a series of 30. [More]
Source: Scientific American Topic - Biotechnology - June 11, 2012 Category: Biotechnology Tags: More Science,Chemistry,Physics,Biotechnology,Biotechnology,Biology,Technology Source Type: news
A Countdown to a Digital Simulation of Every Last Neuron in the Human Brain (preview)
Reductionist biology--examining individual brain parts, neural circuits and molecules--has brought us a long way, but it alone cannot explain the workings of the human brain, an information processor within our skull that is perhaps unparalleled anywhere in the universe. We must construct as well as reduce and build as well as dissect. To do that, we need a new paradigm that combines both analysis and synthesis. The father of reductionism, French philosopher René Descartes, wrote about the need to investigate the parts and then reassemble them to re-create the whole. [More]
Source: Scientific American Topic - Biotechnology - June 11, 2012 Category: Biotechnology Tags: Mind & Brain,Computing,Technology,Society Policy,Everyday Science,More Science,Science Education,Neuroscience,Thought Cognition,Biotechnology,Biotechnology,Medical Technology,Communications,Biology,Health Source Type: news
Cost-based pricing to hit exports, says Indian Pharmaceutical Alliance
A Group of Ministers is finalising the National Pharmaceutical Pricing Policy (NPPP), which seeks to fix the prices of 348 essential drugs.
Source: The Economic Times Healthcare and Biotech News - June 8, 2012 Category: Pharmaceuticals Source Type: news
GSK extends Human Genome Sciences offer
The UK-based pharmaceutical group has put back the deadline on its $2.6bn hostile bid, which its US biotech target has rejected as ‘inadequate’
Source: FT.com - Drugs and Healthcare - June 8, 2012 Category: Pharmaceuticals Source Type: news
Blaze Bioscience Raises $5.0 Million in Series A Financing
Tumor Paint advances towards clinic
SEATTLE--(Healthcare Sales & Marketing Network)--Blaze Bioscience, Inc., a privately held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patie... Biopharmaceuticals, Oncology, Surgery, Venture CapitalBlaze Bioscience, Tumor Paint
Source: HSMN NewsFeed - June 8, 2012 Category: Pharmaceuticals Source Type: news
RNA Silencing and Antiviral Defense in Plants
Given the widespread impact of RNA silencing on the Arabidopsis thaliana genome, it is indeed remarkable that this means of gene regulation went undiscovered for so long. Since the publication of landmark papers in 1998 (Fire et al., Nature 391:806–811, 1998; Waterhouse et al., Proc Natl Acad Sci U S A 95:13959–13964, 1998), intense research efforts have resulted in much progress from the speculation of Mello and colleagues that “the mechanisms underlying RNA interference probably exist for a biological purpose” (Fire et al., Nature 391:806–811, 1998). Across the eukaryotic kingdom, with the n...
Source: Springer protocols feed by Plant Sciences - June 8, 2012 Category: Biology Source Type: news
Delivery of healthcare service via mobile 'inevitable': Survey
Adoption of mobile technology in healthcare or mHealth is "inevitable" as it is likely to improve the way customers communicate with their physicians.
Source: The Economic Times Healthcare and Biotech News - June 8, 2012 Category: Pharmaceuticals Source Type: news
Biotech Firm Synedgen Reports Promising Research Findings on New...
Synedgen Reports Promising Radiation Treatment Data(PRWeb June 08, 2012)Read the full story at http://www.prweb.com/releases/2012/6/prweb9580365.htm
Source: PRWeb: Medical Pharmaceuticals - June 8, 2012 Category: Pharmaceuticals Source Type: news
Piramal Healthcare completes acquisition of US-based firm Decision Resources Group
Piramal Healthcare Ltd today said it has completed acquisition of the US-based Decision Resources Group (DRG) for $635 mn (nearly Rs 3,400 cr).
Source: The Economic Times Healthcare and Biotech News - June 8, 2012 Category: Pharmaceuticals Source Type: news
Advaxis completes patient enrolment in cohort two of Phase 2 ADXS-HPV study
Advaxis, a clinical-stage biotechnology company, has enrolled 40 patients in the second of three dose cohorts in a Phase 2 dose escalation study evaluating the safety and efficacy of ADXS-HPV to treat cervical intraepithelial neoplasia (CIN) 2/3.
Source: Drug Development Technology - June 7, 2012 Category: Pharmaceuticals Source Type: news
Fetal Genome Deduced from Parental DNA
From Nature magazine [More]
Source: Scientific American Topic - Biotechnology - June 7, 2012 Category: Biotechnology Tags: Health,Society & Policy,Medical Technology,Biotechnology,Ethics,Biology,More Science Source Type: news
Panel to look into Drug Controller General of India's working meets
A panel will look into the findings of the 59th Report of the Parliamentary Standing Committee on the functioning of the Central Drugs Standard Control Organisation.
Source: The Economic Times Healthcare and Biotech News - June 7, 2012 Category: Pharmaceuticals Source Type: news
Cipla losses appeal in US court for animal healthcare product
Drug firm Cipla today said it has lost an appeal in a US court over a patent case against Merial Ltd regarding an animal healthcare product.
Source: The Economic Times Healthcare and Biotech News - June 7, 2012 Category: Pharmaceuticals Source Type: news
Concord Biotech plans overseas foray, invest $20 million
Ahmedabad-based Concord Biotech will invest $20 million in setting up a fermentation facility abroad to save on power and fuel costs.
Source: The Economic Times Healthcare and Biotech News - June 7, 2012 Category: Pharmaceuticals Source Type: news
OxThera Resumes Clinical Development of Hyperoxaluria Therapy
STOCKHOLM, June 7, 2012 (HSMN NewsFeed) --OxThera AB, a Stockholm-based privately-held biotechnology company, today announced that it has decided to resume clinical development in primary hyperoxaluria. Together with the company program investigating ent... BiopharmaceuticalsOxThera, hyperoxaluria, Oxabact
Source: HSMN NewsFeed - June 7, 2012 Category: Pharmaceuticals Source Type: news
Nigeria: 'Nation Needs Strong Biosafety Institution'
[Daily Trust]
A group of experts under the auspices of the African Biosafety Network of Expertise (ABNE) in collaboration with the Federal Ministry of Environment at a workshop in Abuja have stressed the need for Nigeria to put in place a strong biosafety institution to guide against the misuse of biotechnology.
Source: AllAfrica News: Health and Medicine - June 7, 2012 Category: African Health Source Type: news
Dr Reddy's launches Parkinson's drug in US
Dr Reddy's Laboratories has launched in the US market Ropinirole Hydrochloride XR (extended release) tablets used to treat the signs and symptoms of Parkinson's disease.
Source: The Economic Times Healthcare and Biotech News - June 7, 2012 Category: Pharmaceuticals Source Type: news
Dr Reddy's and Merck KGaA to develop portfolio of biosimilar drugs
Both the companies will jointly commercialise the compounds in the US market, and Merck will commercialise the deal in 150 countries, except emerging markets .
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
Inter-ministerial panel to finalise norms for MNC buys in drug companies
An eight-member panel will lay down the guidelines by the month-end that will deal with the basic concerns expressed by various stakeholders.
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
U.S. Marshals seized misbranded drugs in Maine
On May 31, 2012, at the request of the U.S. Food and Drug Administration, U.S. Marshals seized drug products from Global Biotechnologies, Inc., of Portland, Maine, pursuant to a warrant issued by the U.S. District Court for the District of Maine.
Source: Food and Drug Administration - June 6, 2012 Category: American Health Source Type: news
Vitamin D - Which Type Is Best?
Although vitamin D is essential for healthy bones and muscles, the majority of people do not get enough of it through exposure to sunlight or through diet. Now, researchers have found that vitamin D3 supplements appear to provide more benefit than vitamin D2. The study, conducted by researchers at the University of Surrey and funded by the Biotechnology and Biological Sciences Research Council (BBSRC), is published in The American Journal of Clinical Nutrition...
Source: Health News from Medical News Today - June 6, 2012 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news
Sal Pharma and Pan Drugs gets FDA warning letter for not registering drugs
Pan Drugs and Sal Pharma have got Warning Letters from American drug regulator for not fulfilling the mandatory registration requirements.
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
Seven Emerging Life Science Clusters in the United States May Provide Business Opportunities for Clinical Pathology Laboratories
Local medical laboratories and pathology groups can often contract to provide certain services to nearby biotechnology firms Clinical laboratories and pathology groups lucky enough to be located near one of the nation’s recognized “life science clusters” have an opportunity to create useful business relationships with the pharmaceutical firms, biotechnology companies, and medical device businesses that [...]
Source: Dark Daily - June 6, 2012 Category: Laboratory Medicine Authors: jude Tags: Laboratory Hiring & Human Resources Laboratory News Laboratory Operations Laboratory Pathology biocluster biotech CBRE Group clinical laboratory Dino Perazzo Genetic Engineering News in vitro diagnostics Inc. IVD Jones Lang Lasal Source Type: news
Dr Reddy's, Merck to jointly develop biosimilars
manufacturing of the compounds and will lead phase-III development.
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
Trinity Biotech plc Announces Details of Its Dividend and Share Buyback Program
DUBLIN, Ireland, June 6, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced additional details of its Dividend and Share Buyback Program.
Source: Medical News (via PRIMEZONE) - June 6, 2012 Category: Pharmaceuticals Source Type: news
Ex-IMG South Asia MD Ravi Krishnan, Shane Bilsborough launch Stepathlon Lifestyle
The company aims at creating an ecosystem that promotes corporate health, fitness and productivity by increasing a person's daily activity through a unique initiative called 'Stepathlon'.
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
Dr Reddy's, Merck Serono in Drug Pact
Indian generic-drug maker Dr. Reddy's Laboratories unveiled a research pact with Germany's Merck aimed at developing biotechnology drugs that can be sold in the highly regulated but more lucrative markets of the U.S., Europe and Japan.
Source: WSJ.com: Health - June 6, 2012 Category: Pharmaceuticals Tags: FREEINDIA Source Type: news
Dr Reddy's and Merck KGaA to develop portfolio of biosimilar drugs
Dr. Reddy's and Merck Serono announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology.
Source: The Economic Times Healthcare and Biotech News - June 6, 2012 Category: Pharmaceuticals Source Type: news
